欧洲骨髓瘤网络关于罕见浆细胞病诊断与管理的推荐
欧洲骨髓瘤网络更新了华氏巨球蛋白血症、AL淀粉样变性、单克隆免疫球蛋白沉积病、POEMS综合征和原发性浆细胞白血病的诊断与治疗推荐。华氏巨球蛋白血症以利妥昔单抗联合化疗为基石,依鲁替尼获批用于复发/难治;AL淀粉样变性伴心脏受累时不推荐自体干细胞移植强化;POEMS综合征局限期用放疗,播散期系统治疗但避免加重多神经病的方案;原发性浆细胞白血病需多阶段新药治疗。
要点
- 华氏巨球蛋白血症治疗基石为利妥昔单抗联合化疗,依鲁替尼已获批用于复发/难治。
- AL淀粉样变性伴心脏受累时,不推荐自体干细胞移植强化治疗。
- POEMS综合征局限期放疗可获持久缓解,播散期系统治疗应避免加重多神经病的方案。
核心结论
- 欧洲骨髓瘤网络更新了五种罕见浆细胞病的诊断和治疗推荐,新药引入改变了治疗策略和患者结局。
研究设计与样本
- 欧洲骨髓瘤网络(European Myeloma Network)更新诊断与治疗推荐,覆盖华氏巨球蛋白血症、AL淀粉样变性、单克隆免疫球蛋白沉积病、POEMS综合征和原发性浆细胞白血病。
主要发现
- 华氏巨球蛋白血症:利妥昔单抗联合化疗仍是治疗基石,布鲁顿酪氨酸激酶抑制剂依鲁替尼已引入并获批用于复发/难治性疾病。
- AL淀粉样变性:管理取决于心脏功能障碍的存在和严重程度;若存在,不推荐自体干细胞移植强化;多西环素或靶向淀粉样沉积的单克隆抗体可预防错误折叠轻链进一步聚集;初始治疗通常为美法仑/地塞米松或含硼替佐米的方案;复发患者可考虑蛋白酶体抑制剂、免疫调节剂、美法仑或达雷妥尤单抗。
- 单克隆免疫球蛋白沉积病:完整或轻链免疫球蛋白是致病原因,小的单克隆浆细胞克隆应被治疗,通常对含硼替佐米的治疗反应良好。
- POEMS综合征:可表现为孤立性骨病变或播散性疾病;局部病变采用放疗并获持久缓解;播散性疾病应系统治疗,但应避免可加重已有多种经病的方案。
- 原发性浆细胞白血病:病程侵袭、预后差,需立即多阶段含新药治疗,包括诱导、自体干细胞移植、巩固和维持,无治疗间隔短;不适合移植者需个体化强化治疗;特定患者可用异基因干细胞移植。
关键数值与推荐
- 华氏巨球蛋白血症:利妥昔单抗联合化疗为治疗基石;依鲁替尼获批用于复发/难治性疾病。
- AL淀粉样变性:伴心脏功能障碍时不推荐自体干细胞移植强化;初始治疗通常为美法仑/地塞米松或含硼替佐米方案;复发可考虑蛋白酶体抑制剂、免疫调节剂、美法仑或达雷妥尤单抗。
- POEMS综合征:局限性疾病采用放疗;播散性疾病应系统治疗,避免加重多种经病的方案。
- 原发性浆细胞白血病:需含新药的多阶段治疗(诱导、自体干细胞移植、巩固、维持),无治疗间隔短;不适合移植者个体化强化治疗;特定患者可行异基因干细胞移植。
临床怎么用
- 华氏巨球蛋白血症采用利妥昔单抗联合化疗,复发/难治可用依鲁替尼。
- AL淀粉样变性伴心脏受累时不推荐自体干细胞移植强化,初始可选美法仑/地塞米松或含硼替佐米方案。
- POEMS综合征局限期用放疗,播散期系统治疗但避免加重多种经病的方案。
- 原发性浆细胞白血病需立即多阶段含新药治疗,不适合移植者个体化强化,特定患者可行异基因移植。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The introduction of novel agents in the management of multiple myeloma and related plasma cell dyscrasias has changed our treatment approaches and subsequently the outcome of patients. Due to current advances, the European Myeloma Network updated the diagnostic and therapeutic recommendations for patients with Waldenström's macroglobulinemia (WM), AL-amyloidosis, monoclonal immunoglobulin deposition disease (MIDD), POEMS syndrome, and primary plasma cell leukemia. For patients with WM, the combination of rituximab with chemotherapy remains the treatment cornerstone, while the Bruton-tyrosine kinase inhibitor ibrutinib has been introduced and approved for relapsed/refractory disease. The management of light chain amyloidosis depends on the presence and severity of heart disfunction. If present, intensification with an autologous stem cell transplantation (ASCT) is not recommended. Further aggregation of misfolded light chains could be prevented by doxycycline or monoclonal antibodies targeting amyloid deposits. Initial treatment generally consists of melphalan/dexamethasone or bortezomib-based regimens. For relapsing patients, one can consider proteasome inhibitors, immunomodulatory agents, melphalan or daratumumab. Because intact or light-chain immunoglobulins are also the culprits for MIDD, the small monoclonal plasma cells' clones should be treated and generally respond well to bortezomib-based treatment. POEMS syndrome is a well-defined clinical entity that can present as solitary bone lesions or disseminated disease. Radiation therapy is used for patients with localized disease and result in long-lasting response. Systemic treatment should be proposed to patients with disseminated disease, but regimens that can worsen a pre-existing polyneuropathy should be avoided. PPCL is located at the other end of the spectrum of plasma cell disorders and is associated with an aggressive disease course and poor prognosis. It requires an imminent, multi-phase and novel agents-based therapy, including induction, ASCT, consolidation and maintenance, with short treatment-free intervals. Patients not eligible for transplant procedures require personalized, intensive therapeutic approach. Allogeneic stem cell transplantation can be used in selected patients.
引用
- Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018. PMID: 30038381. doi:10.1038/s41375-018-0209-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。